Bavarian Nordic completes a private placing of new shares for a total amount of DKK 1,642 million

On 20 February 2023, Bavarian Nordic A/S announced the launch of a private placing of new ordinary shares, at a price to be determined through an accelerated book-building process. The private placing has been completed and was priced at DKK 233 per share, raising gross proceeds to Bavarian Nordic of approx. DKK 1,642 million.

The net proceeds from the placing are intended to be used for payment of the purchase price in respect of the Bavarian Nordic’s contemplated acquisition of a portfolio of travel vaccines from Emergent BioSolutions as announced by Bavarian Nordic on 15 February 2023.

Through the acquisition, Bavarian Nordic:

• adds two revenue-generating vaccines for the prevention of cholera and typhoid fever that will establish Bavarian Nordic as a global leader in travel vaccines,
• broadens its development pipeline with a late-stage Chikungunya vaccine candidate with significant synergistic market opportunity in areas with a high unmet medical need
• expands its manufacturing footprint and flexibility with facility in Switzerland and adds research competences with facility in San Diego, CA

We have assisted Bavarian Nordic in connection with the accelerated book-building and private placing. Danske Bank A/S, Morgan Stanley & Co. International plc and Nordea Danmark, Filial af Nordea Bank Abp, Finland acted as Joint Global Coordinators and Joint Bookrunners.

Read more (in Danish): Bavarian har solgt 7 mio. aktier for 233 kr. per aktie (borsen.dk) (behind paywall)

About Bavarian Nordic

Bavarian Nordic is a fully integrated vaccines company focused on the research and development, manufacturing and commercialization of life-saving vaccines. Bavarian Nordic are a global leader in smallpox and mpox vaccines, which have been developed through its long-standing partnership with the U.S. Government to enhance the public health preparedness. Bavarian Nordic's commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using its live virus vaccine platform technology, MVA-BN® and in-licensed technologies, they have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including late-stage development programs for an RSV vaccine for older adults and a next generation COVID-19 vaccine.